Advertisement
UK markets close in 1 hour 48 minutes
  • FTSE 100

    7,960.33
    +28.35 (+0.36%)
     
  • FTSE 250

    19,874.12
    +63.46 (+0.32%)
     
  • AIM

    743.91
    +1.80 (+0.24%)
     
  • GBP/EUR

    1.1697
    +0.0028 (+0.24%)
     
  • GBP/USD

    1.2643
    +0.0005 (+0.04%)
     
  • Bitcoin GBP

    56,480.26
    +1,009.74 (+1.82%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,251.78
    +3.29 (+0.06%)
     
  • DOW

    39,739.99
    -20.09 (-0.05%)
     
  • CRUDE OIL

    82.36
    +1.01 (+1.24%)
     
  • GOLD FUTURES

    2,228.30
    +15.60 (+0.71%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,486.24
    +9.15 (+0.05%)
     
  • CAC 40

    8,212.16
    +7.35 (+0.09%)
     

Tiziana Life Sciences Announces Purchase of Common Shares by Chief Medical Officer

Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd.

NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Matthew Davis, its Chief Medical Officer, purchased 100,000 common shares at $0.76 per share.

About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further inquiries:

Tiziana Life Sciences Ltd

Hana Malik, Business Development, and Investor Relations Manager  
+44 (0) 207 495 2379
email: info@tizianalifesciences.com 

Investors:
Irina Koffler
LifeSci Advisors, LLC
646.970.4681
ikoffler@lifesciadvisors.com